ADLM Guidance Document on Coagulation Testing in Patients Using Direct Oral Anticoagulants
- 4 November 2025
- journal article
- practice guideline
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 10 (6) , 1675-1690
Abstract
Background: Coagulation testing has an important role in the diagnosis, monitoring, and therapeutic decision-making for patients with abnormal hemostasis. As the field of anticoagulation options has expanded, the introduction of direct oral anticoagulant (DOAC) drugs has provided an option for patients utilizing drugs that do not require routine monitoring. Patients on these drugs may still need coagulation testing for prognostic purposes, and there are a number of nuances to consider when performing coagulation testing in patients who are prescribed DOACs. Content: This document provides guidance on the tests that may or may not be impacted by the presence of DOACs in the blood. A discussion is provided about specific coagulation tests used and the impact of testing samples with a DOAC present. Options are presented to help mitigate the impact of DOACs on the testing. In addition, this document discusses how to test for and interpret DOAC concentrations in specific patient populations.Keywords
This publication has 83 references indexed in Scilit:
- Impact of Factor Xa Inhibition on Coagulation, Platelet Reactivity, and Thrombosis in Patients with Peripheral Artery DiseaseAnnals of Vascular Surgery, 2023
- Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samplesResearch and Practice in Thrombosis and Haemostasis, 2022
- Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs)Current Pharmacology Reports, 2020
- Edoxaban affects TRAP-dependent platelet aggregationJournal of Thrombosis and Thrombolysis, 2020
- Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trialsResearch and Practice in Thrombosis and Haemostasis, 2018
- Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent mannerJournal of Thrombosis and Thrombolysis, 2017
- Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial FibrillationJAMA Cardiology, 2017
- Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to KnowPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanClinical Pharmacokinetics, 2013
- The use of activated clotting times to monitor heparin therapy during and after interventional proceduresClinical Cardiology, 1994